Last reviewed · How we verify
Rituximab Fludarabine Cyclophosphamide
Rituximab Fludarabine Cyclophosphamide is a Small molecule drug developed by Asociacion Espanola de Hematologia y Hemoterapia. It is currently FDA-approved. Also known as: MABTHERA, BENEFLUR, GENOXAL.
Rituximab Fludarabine Cyclophosphamide, marketed by Asociacion Espanola de Hematologia y Hemoterapia, is a combination therapy currently available in the market. The key composition patent for this drug is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Rituximab Fludarabine Cyclophosphamide |
|---|---|
| Also known as | MABTHERA, BENEFLUR, GENOXAL |
| Sponsor | Asociacion Espanola de Hematologia y Hemoterapia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (PHASE2)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (PHASE3)
- A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) (PHASE3)
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (PHASE3)
- Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies (PHASE2)
- A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab Fludarabine Cyclophosphamide CI brief — competitive landscape report
- Rituximab Fludarabine Cyclophosphamide updates RSS · CI watch RSS
- Asociacion Espanola de Hematologia y Hemoterapia portfolio CI
Frequently asked questions about Rituximab Fludarabine Cyclophosphamide
What is Rituximab Fludarabine Cyclophosphamide?
Who makes Rituximab Fludarabine Cyclophosphamide?
Is Rituximab Fludarabine Cyclophosphamide also known as anything else?
What development phase is Rituximab Fludarabine Cyclophosphamide in?
Related
- Manufacturer: Asociacion Espanola de Hematologia y Hemoterapia — full pipeline
- Also known as: MABTHERA, BENEFLUR, GENOXAL
- Compare: Rituximab Fludarabine Cyclophosphamide vs similar drugs
- Pricing: Rituximab Fludarabine Cyclophosphamide cost, discount & access